The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to R T I International to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product development...
Altasciences Clinical Kansas Inc. was awarded a single-award indefinite delivery contract from the Department of Health and Human Services Food and Drug Administration valued at up to $5 million. The contract aims to advance generic drug approvals through the conduct of bioequivalence studies and characterization of generic drugs. Three firm fixed price delivery orders have been issued against this contract to date, with places of performance in Overland Park, Kansas. The first delivery order,...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (NIDA) awarded a single-award $21 million indefinite delivery contract to Altasciences Clinical Kansas Inc., a contract research organization, to conduct pharmacokinetic and pharmacodynamic trials for medication development in substance use disorders. Under this contract, NIDA issued a $1,838,615 firm fixed price delivery order to Altasciences to perform Phase 1 cocaine drug interaction...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), awarded a $346.6 million multiple-award Indefinite Delivery Contract (IDC) called the Early Phase Clinical Trial Units (EPCTU) program. This IDC supports Phase 0 through Phase III clinical trials of investigational products against infectious diseases, including small molecules, monoclonal antibodies, vaccines, and other medical countermeasures. The prime...
The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded an indefinite delivery contract to Pharmaceutical Research Associates Inc., doing business as PRA, with a potential value of $250 million. The contract provides for clinical trials planning and execution services in support of the Clinical Studies Network. PRA was issued a $200,000 delivery order for one base year of performance ending September 2021 to conduct clinical trial...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to American Type Culture Collection to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables task orders to be issued across five areas: product...
The National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial discovery to clinical trials. Services are conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development, preclinical pharmacology and...